12% growth projection is far higher than many analysts have arrived at. Analysts are projecting a drop off after covid. https://www.marketscreener.com/quote...30/financials/
I am reasonably confident of which ones have a better understanding of the business
What's this after Covid though?
Covid is still here and spreading.
What's this after Covid though?
Covid is still here and spreading.
In a post-vaccinated world, COVID-19 may well continue to spread, but overall the physiological impact will be much less than we're seeing today. The unvaccinated, the long-haul sufferers and other similar groups will still require the types of products that FPH produce, but demand shouldn't continue to grow at the same rate is has in the past.
For those that don't wish to read through entire presentations
FPH have short(Hospital respiratory support), medium(Home respiratory support) and long term (Surgical technologies) growth covered
pg 5-7 investor series https://www.fphcare.com/nz/our-compa...estor/reports/
Future is bright for FPH ...but short term uncertainty will make the stock underperform . Medium to long term exceptionally positive .
From 10% revenue growth target has been upgraded to 12 % ...thats how positive management is feeling after this covid exposure on the world stage .
I am sure many smarter analysts will also take note of brighter future ahead ...consensus 0.62 cents eps is too pessimistic IMHO ...more like between 0.70-0.80 range depending upon how covid behaves ahead . So Craigs target of around $ 34 seems very realistic with upside surprise possibly .
FPH SP needs time to settle down ....last August it was $ 38 in expectations of these results which just revealed ....now its $ 29 in anticipation of sales falling fully !
In the bigger scenario current calendar is small up or down movement only ...30- 35 . Look for it in calendar 22 and 23 .
Future is bright for FPH ...but short term uncertainty will make the stock underperform . Medium to long term exceptionally positive .
From 10% revenue growth target has been upgraded to 12 % ...thats how positive management is feeling after this covid exposure on the world stage .
I am sure many smarter analysts will also take note of brighter future ahead ...consensus 0.62 cents eps is too pessimistic IMHO ...more like between 0.70-0.80 range depending upon how covid behaves ahead . So Craigs target of around $ 34 seems very realistic with upside surprise possibly .
FPH SP needs time to settle down ....last August it was $ 38 in expectations of these results which just revealed ....now its $ 29 in anticipation of sales falling fully !
In the bigger scenario current calendar is small up or down movement only ...30- 35 . Look for it in calendar 22 and 23 .
Abbott techology down 10% today.. The market tends to have a rather low attention span.
Tests are no lonnger needed when corona is not around who knew.
Though they too have a long history of growing rev/earnings.
Kiwi ventilator manufacturer F&P Healthcare led the market higher, leaping 5.6% to $30.75, with investors trading almost $30 million worth of stock.
Hamilton Hindin Greene investment adviser, Grant Davies said the move was likely driven by the news that Royal Phillips – better known just as Phillips – had recalled 4 million to 5m ventilators and sleep apnoea devices.
The Dutch company found possible health risks with a polyester-based foam used for sound absorption in the products. This sent its share price tumbling more than 4% and shaved a billion dollars off its market capitalisation.
With new developments about big product recall by number 2 sleep apnea device maker Philips thus taking them out of the market for next 18 months as indicated by their own spokesperson ...also said will lead to shortage of devices in the short term . This gives number 3 manufacturer FPH a great chance to boost its market share in Homecare segment . Its very possible they maybe able to win extra $ 200 million sales in this segment which will help cover majority of the hospital division shortfall for the current year IMHO ...Makes holding FPH even more interesting as knowing the management ...they will surely try to cash on this opportunity fully ..their weaker segment Home Care . RMD has 43% market share Philips 31% and FPH 12% ...with Philips out for medium term plus the damage this recall will do to their reputation ....hopefully FPH should capitalise big .
Originally Posted by kiora
Reply With Quote
Bookmarks